Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in <scp>HBV</scp>‐infected individuals treated with pegylated interferon—Implications for stopping rules and the <scp>HBV</scp> cure programme. Authors' reply-Reference-Cited by-同舟云学术

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply

Published:2024-07-17 Issue:5 Volume:60 Page:652-653
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Xie Chan¹^ORCID

Affiliation:

1. Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou China

Abstract

LINKED CONTENTThis article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18142

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18174

Reference8 articles.

1. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme

2. Functional cure based on Pegylated interferon ɑ‐2b therapy in nucleoside analog‐suppressed HBeAg negative chronic hepatitis B: a multicenter real‐world study (Everest project in China)—4 years data update;Mo Z;Hepatology,2022

3. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience

4. Peg‐interferon alpha add‐on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg‐positive chronic hepatitis B naïve patients

5. Review article: novel biomarkers in hepatitis B infection